Literature DB >> 28483947

Regulation of USP37 Expression by REST-Associated G9a-Dependent Histone Methylation.

Tara H W Dobson1, Rashieda J Hatcher1, Jyothishmathi Swaminathan1, Chandra M Das1, Shavali Shaik1, Rong-Hua Tao1, Ciro Milite2, Sabrina Castellano2, Pete H Taylor1, Gianluca Sbardella2, Vidya Gopalakrishnan3,4,5,6,7.   

Abstract

The deubiquitylase (DUB) USP37 is a component of the ubiquitin system and controls cell proliferation by regulating the stability of the cyclin-dependent kinase inhibitor 1B, (CDKN1B/p27Kip1). The expression of USP37 is downregulated in human medulloblastoma tumor specimens. In the current study, we show that USP37 prevents medulloblastoma growth in mouse orthotopic models, suggesting that it has tumor-suppressive properties in this neural cancer. Here, we also report on the mechanism underlying USP37 loss in medulloblastoma. Previously, we observed that the expression of USP37 is transcriptionally repressed by the RE1 silencing transcription factor (REST), which requires chromatin remodeling factors for its activity. Genetic and pharmacologic approaches were employed to identify a specific role for G9a, a histone methyltransferase (HMT), in promoting methylation of histone H3 lysine-9 (H3K9) mono- and dimethylation, and surprisingly trimethylation, at the USP37 promoter to repress its gene expression. G9a inhibition also blocked the tumorigenic potential of medulloblastoma cells in vivo Using isogenic low- and high-REST medulloblastoma cells, we further showed a REST-dependent elevation in G9a activity, which further increased mono- and trimethylation of histone H3K9, accompanied by downregulation of USP37 expression. Together, these findings reveal a role for REST-associated G9a and histone H3K9 methylation in the repression of USP37 expression in medulloblastoma.Implications: Reactivation of USP37 by G9a inhibition has the potential for therapeutic applications in REST-expressing medulloblastomas. Mol Cancer Res; 15(8); 1073-84. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28483947      PMCID: PMC5540785          DOI: 10.1158/1541-7786.MCR-16-0424

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  51 in total

1.  Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase.

Authors:  Stefan Kubicek; Roderick J O'Sullivan; E Michael August; Eugene R Hickey; Qiang Zhang; Miguel L Teodoro; Stephen Rea; Karl Mechtler; Jennifer A Kowalski; Carol Ann Homon; Terence A Kelly; Thomas Jenuwein
Journal:  Mol Cell       Date:  2007-02-09       Impact factor: 17.970

2.  Interaction of the S phase regulator cdc18 with cyclin-dependent kinase in fission yeast.

Authors:  G W Brown; P V Jallepalli; B J Huneycutt; T J Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

3.  Skp1-Cul1-F-box ubiquitin ligase (SCF(βTrCP))-mediated destruction of the ubiquitin-specific protease USP37 during G2-phase promotes mitotic entry.

Authors:  Amy C Burrows; John Prokop; Matthew K Summers
Journal:  J Biol Chem       Date:  2012-10-01       Impact factor: 5.157

Review 4.  Proteasome deubiquitinases as novel targets for cancer therapy.

Authors:  Pádraig D'Arcy; Stig Linder
Journal:  Int J Biochem Cell Biol       Date:  2012-07-20       Impact factor: 5.085

5.  USP37 deubiquitinates Cdt1 and contributes to regulate DNA replication.

Authors:  Santiago Hernández-Pérez; Elisa Cabrera; Hugo Amoedo; Sara Rodríguez-Acebes; Stephane Koundrioukoff; Michelle Debatisse; Juan Méndez; Raimundo Freire
Journal:  Mol Oncol       Date:  2016-06-03       Impact factor: 6.603

6.  Relationship between histone H3 lysine 9 methylation, transcription repression, and heterochromatin protein 1 recruitment.

Authors:  M David Stewart; Jiwen Li; Jiemin Wong
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

7.  The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells.

Authors:  P Lawinger; R Venugopal; Z S Guo; A Immaneni; D Sengupta; W Lu; L Rastelli; A Marin Dias Carneiro; V Levin; G N Fuller; Y Echelard; S Majumder
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

8.  Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: separate regulation of mammalian target of rapamycin activity and p27 Kip1 localization.

Authors:  Bobby Bhatia; Paul A Northcott; Dolores Hambardzumyan; Baskaran Govindarajan; Daniel J Brat; Jack L Arbiser; Eric C Holland; Michael D Taylor; Anna Marie Kenney
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

Review 9.  Medulloblastoma: Tumor Biology and Relevance to Treatment and Prognosis Paradigm.

Authors:  Daniel Coluccia; Carlyn Figuereido; Semra Isik; Christian Smith; James T Rutka
Journal:  Curr Neurol Neurosci Rep       Date:  2016-05       Impact factor: 5.081

10.  Histone H3 lysine 9 methyltransferase G9a is a transcriptional coactivator for nuclear receptors.

Authors:  David Y Lee; Jeffrey P Northrop; Min-Hao Kuo; Michael R Stallcup
Journal:  J Biol Chem       Date:  2006-02-04       Impact factor: 5.157

View more
  18 in total

1.  Phosphatase activity of small C-terminal domain phosphatase 1 (SCP1) controls the stability of the key neuronal regulator RE1-silencing transcription factor (REST).

Authors:  Nathaniel Tate Burkholder; Joshua E Mayfield; Xiaohua Yu; Seema Irani; Daniel K Arce; Faqin Jiang; Wendy L Matthews; Yuanchao Xue; Yan Jessie Zhang
Journal:  J Biol Chem       Date:  2018-09-14       Impact factor: 5.157

Review 2.  Proteins and Proteoforms: New Separation Challenges.

Authors:  Fred E Regnier; JinHee Kim
Journal:  Anal Chem       Date:  2017-12-18       Impact factor: 6.986

Review 3.  Epigenetic regulation in medulloblastoma.

Authors:  Jiaqing Yi; Jiang Wu
Journal:  Mol Cell Neurosci       Date:  2017-12-18       Impact factor: 4.314

Review 4.  Medulloblastoma epigenetics and the path to clinical innovation.

Authors:  Amanda R Haltom; Stephanie A Toll; Donghang Cheng; Shinji Maegawa; Vidya Gopalakrishnan; Soumen Khatua
Journal:  J Neurooncol       Date:  2020-08-20       Impact factor: 4.130

Review 5.  Lysine methyltransferase inhibitors: where we are now.

Authors:  Alessandra Feoli; Monica Viviano; Alessandra Cipriano; Ciro Milite; Sabrina Castellano; Gianluca Sbardella
Journal:  RSC Chem Biol       Date:  2021-12-13

6.  Chromatin Immunoprecipitation Assays on Medulloblastoma Cell Line DAOY.

Authors:  Tara Dobson; Jyothishmathi Swaminathan
Journal:  Methods Mol Biol       Date:  2022

7.  G9a/EHMT2 is a Potential Prognostic Biomarker and Molecular Target in SHH Medulloblastoma.

Authors:  Barbara Kunzler Souza; Natalia Hogetop Freire; Mariane Jaeger; Caroline Brunetto de Farias; Algemir L Brunetto; André T Brunetto; Rafael Roesler
Journal:  Neuromolecular Med       Date:  2022-02-03       Impact factor: 3.843

8.  Medulloblastoma: novel insights into emerging therapeutic targets.

Authors:  Shavali Shaik; Shinji Maegawa; Vidya Gopalakrishnan
Journal:  Expert Opin Ther Targets       Date:  2021-10-04       Impact factor: 6.797

9.  REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature.

Authors:  Shavali Shaik; Bridget Kennis; Shinji Maegawa; Keri Schadler; Yang Yanwen; Keri Callegari; Rishi R Lulla; Stewart Goldman; Javad Nazarian; Veena Rajaram; Jason Fangusaro; Vidya Gopalakrishnan
Journal:  Oncotarget       Date:  2017-12-28

10.  Transcriptional repressor REST drives lineage stage-specific chromatin compaction at Ptch1 and increases AKT activation in a mouse model of medulloblastoma.

Authors:  Tara H W Dobson; Rong-Hua Tao; Jyothishmathi Swaminathan; Shinji Maegawa; Shavali Shaik; Javiera Bravo-Alegria; Ajay Sharma; Bridget Kennis; Yanwen Yang; Keri Callegari; Amanda R Haltom; Pete Taylor; Mari Kogiso; Lin Qi; Soumen Khatua; Stewart Goldman; Rishi R Lulla; Jason Fangusaro; Tobey J MacDonald; Xiao-Nan Li; Cynthia Hawkins; Veena Rajaram; Vidya Gopalakrishnan
Journal:  Sci Signal       Date:  2019-01-22       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.